CVRx (CVRX) Stock Based Compensation: $11.51 Mil (TTM As of Mar. 2026)


CVRX CVRx Inc CVRX
56 GF Score
Price $5.60
GF Value $11.25
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is CVRx Stock Based Compensation?

CVRx CVRX +1.82% 56 Stock Based Compensation is $11.51 Mil as of Mar. 2026. GuruFocus rates CVRX with a GF Score™ of 56/100 and a GF Value™ of $11.25 (Possible Value Trap). The stock has 4 warning signs investors should review.

CVRx's Stock Based Compensation for the three months ended in Mar. 2026 was $2.92 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $11.51 Mil.

CVRx Stock Based Compensation Related Terms

CVRx Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for CVRx's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CVRx Stock Based Compensation Chart

CVRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 1.91 3.89 6.30 19.05 11.05

CVRx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.46 2.92 2.89 2.79 2.92
CVRX
56GF Score
CVRx Inc CVRX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CVRx Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.51 Mil.

What does a Stock Based Compensation of $11.51 Mil mean?
CVRx (CVRX) has a Stock Based Compensation of $11.51 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CVRx and its competitors.
Is CVRx's Stock Based Compensation too high?
CVRx's current Stock Based Compensation is $11.51 Mil. Overall, CVRx has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CVRx's Stock Based Compensation compare to OWLT and HYPR?
CVRx's Stock Based Compensation of $11.51 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CVRx and its competitors. CVRx's current Stock Based Compensation is $11.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CVRx stock overvalued right now?
Based on GuruFocus' analysis, CVRx (CVRX) is currently considered Possible Value Trap. The stock's GF Value™ is $11.25, compared to a current price of $5.60 — trading 50.3% below its estimated fair value. The current Stock Based Compensation is $11.51 Mil. CVRx's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For CVRx (CVRX), the current Stock Based Compensation is $11.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CVRx (CVRX) Overvalued in 2026?

Based on GuruFocus' analysis, CVRx stock appears to be undervalued. The current stock price of $5.60 is trading 50.3% below its estimated GF Value™ of $11.25. GuruFocus considers CVRx to be Possible Value Trap.

Key valuation signals for CVRX:

  • Stock Based Compensation: $11.51 Mil
  • GF Value™: $11.25 vs. price of $5.60 (50.3% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the CVRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CVRx Business Description

Address 9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
56GF Score

Get the complete analysis for CVRX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.60
Price
$11.25
GF Value